Physician profile
Jonathan Yager
NPI 1043302615
$1,073.48
in general payments reported to CMS, 2019-2025
15 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $196 · 2021: $92.73 · 2022: $72.66 · 2023: $262 · 2024: $33.63 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $328.11 | 2019-2025 | |
| Abbott Laboratories | $144.80 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $137.95 | 2025 | Aurora Ev-Icd Mri Surescan |
| Amgen INC. | $86.79 | 2019-2024 | Otezla, Repatha |
| Medicomp INC | $73.51 | 2023 | Telepatch Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $70.52 | 2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $56.39 | 2019 | |
| Amarin Pharma, INC. | $36.20 | 2019-2021 | |
| Esperion Therapeutics, INC. | $33.88 | 2021 | |
| Novo Nordisk INC | $25.24 | 2025 | Wegovy |
| Boston Scientific Corporation | $20.30 | 2025 | Watchman Access System |
| Merck Sharp & Dohme LLC | $16.83 | 2021 | |
| Astellas Pharma US INC | $16.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.16 | 2022 | |
| Infobionic, INC | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Yager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.